Related Experiment Video
Updated: Jun 17, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Ketoprofen, peginterferon 2a and ribavirin for genotype 1 chronic hepatitis C: a phase II study
Annagiulia Gramenzi1, Carmela Cursaro, Marzia Margotti
1Department of Clinical Medicine, University of Bologna, 40138 Bologna, Italy.
Aim:
To evaluate the safety of adding ketoprofen to pegylated-interferon (PEG-IFN) with or without ribavirin and the effect on viral kinetics, STAT1 activity and expression of 2'-5'-oligoadenylate synthetase (2'-5'OAS) in genotype 1 chronic hepatitis C in a phase II study.
Methods:
Forty-five patients were studied: fifteen were randomized to PEG-IFN plus ribavirin (PR), 16 to PEG-IFN plus ketoprofen and 14 to PR and ketoprofen. The molecular study of IFN-dependent signal transduction was conducted in 9 patients from each group.
Results:
The combination of ketoprofen and PEG-IFN with or without ribavirin was safe and well tolerated. An early activation of STAT1 was observed in ketoprofen-treated patients, but this activation was less sustained over time. Conversely, ketoprofen plus PEG-IFN and ribavirin induced an early and sustained increase of 2'-5'OAS transcription starting 24 h after the first dose until the 36th wk. These data are consistent with the clinical results, showing a better sustained virological response and a lower relapse rate in patients receiving ketoprofen plus PEG-IFN and ribavirin.
Conclusion:
The addition of ketoprofen to the standard therapy of chronic hepatitis C should be explored in larger randomized clinical studies.
Related Concept Videos
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Hepatitis
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Antiviral Nucleoside Inhibitors
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
